Landfar Bio-medicine logo
000504 logo

Landfar Bio-medicineSZSE:000504 Stock Report

Market Cap CN¥3.1b
Share Price
n/a
1Y11.0%
7D-0.7%
Portfolio Value
View

Landfar Bio-medicine Co., Ltd

SZSE:000504 Stock Report

Market Cap: CN¥3.1b

000504 Stock Overview

Operates as a biomedical technology company. More details

000504 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Landfar Bio-medicine Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Landfar Bio-medicine
Historical stock prices
Current Share PriceCN¥9.35
52 Week HighCN¥11.39
52 Week LowCN¥6.05
Beta0.72
1 Month Change4.00%
3 Month Change-7.15%
1 Year Change11.05%
3 Year Change-40.97%
5 Year Change29.14%
Change since IPO388.20%

Recent News & Updates

Some Landfar Bio-medicine Co., Ltd (SZSE:000504) Shareholders Look For Exit As Shares Take 26% Pounding

Jan 03
Some Landfar Bio-medicine Co., Ltd (SZSE:000504) Shareholders Look For Exit As Shares Take 26% Pounding

There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Oct 21
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Recent updates

Some Landfar Bio-medicine Co., Ltd (SZSE:000504) Shareholders Look For Exit As Shares Take 26% Pounding

Jan 03
Some Landfar Bio-medicine Co., Ltd (SZSE:000504) Shareholders Look For Exit As Shares Take 26% Pounding

There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Oct 21
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Jun 09
Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Apr 17
Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Mar 01
Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Shareholder Returns

000504CN BiotechsCN Market
7D-0.7%4.1%1.3%
1Y11.0%-9.7%16.8%

Return vs Industry: 000504 exceeded the CN Biotechs industry which returned -10.4% over the past year.

Return vs Market: 000504 underperformed the CN Market which returned 17.3% over the past year.

Price Volatility

Is 000504's price volatile compared to industry and market?
000504 volatility
000504 Average Weekly Movement6.4%
Biotechs Industry Average Movement5.2%
Market Average Movement6.3%
10% most volatile stocks in CN Market10.4%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 000504 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 000504's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991n/aChangqiao Youwww.landfar.cn

Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. The company operates through Biomedicine, and Energy Saving and Environmental Protection segments. The Biomedicine segment engages in the provision of stem cell storage and technical services; stem cell therapy research; medical device procurement and sales, etc. The Energy Saving and Environmental Protection segment is involved in the external energy management contract energy management business; build-transfer business and sales of related products; and sewage treatment business.

Landfar Bio-medicine Co., Ltd Fundamentals Summary

How do Landfar Bio-medicine's earnings and revenue compare to its market cap?
000504 fundamental statistics
Market capCN¥3.09b
Earnings (TTM)-CN¥37.07m
Revenue (TTM)CN¥124.45m

24.8x

P/S Ratio

-83.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
000504 income statement (TTM)
RevenueCN¥124.45m
Cost of RevenueCN¥40.02m
Gross ProfitCN¥84.43m
Other ExpensesCN¥121.50m
Earnings-CN¥37.07m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)-0.11
Gross Margin67.84%
Net Profit Margin-29.79%
Debt/Equity Ratio4.4%

How did 000504 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 02:40
End of Day Share Price 2025/02/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Landfar Bio-medicine Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.